Azenta recasts historical financials to reflect B Medical Systems as discontinued operations held for sale

Azenta, Inc.

For FY2024 (12 months ended Sep 30, 2024), continuing ops revenue $573.2M, operating loss $50.6M.
Discontinued ops (B Medical) posted net loss of $140.5M for FY2024, classified as held for sale since Nov 12, 2024.
Recast data covers multiple prior periods to help investors isolate core Sample Management & Multiomics segments.
Sale of B Medical is intended to simplify portfolio and focus on core revenue growth and profitability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.